3 December 2019 - - French clinical-stage biotech company Sensorion (PAR: ALSEN) has reported results from a Phase 2 proof-of-concept trial of SENS-111 for the treatment of acute unilateral vestibulopathy, the company said.

SENS-111 was safe and well tolerated. However, it did not meet the primary endpoint of vertigo intensity, measured by the area under the curve of the vertigo intensity visual analogue scale (VI-VAS) in standing position over the four treatment days, with eight post baseline assessments.

The SENS-111 phase 2b proof-of-concept trial was a randomized, double-blind, placebo-controlled study, which had three parallel arms and evaluated the efficacy and safety of SENS-111 histamine H4 receptor antagonist.

A total of 105 patients were included in the study, conducted in Europe, Israel, South Korea and the United States, with a 1: 1: 1 randomisation ratio, stratified by duration of vertigo before treatment (≤24 hours, >24 hours).

Each patient participated in the study for four weeks, with four days of double-blind treatment and a follow up with no investigational product until 28 days after inclusion.

SENS-111 (Seliforant) is an orally available small molecule histamine type 4 receptor antagonist, displaying an inhibitory effect on vestibular neuron activity.

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders.

Its clinical-stage portfolio includes one phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL).

Sensorion has built a unique R and D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates.

The company has also identified biomarkers to improve diagnosis and treatment of these underserved illnesses.

Sensorion has launched in the second half of 2019 two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin.

The company is placed through its platforms and pipeline of potential therapeutics to make an impact on hundreds of thousands of people with inner ear related disorders.